{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-265937","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.699022+00:00","generated_at":"2026-05-17T00:16:43.731784+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"confidence":"high","headline":"Tempest reports Q3 net loss $3.5M, cash $7.5M; continues strategic alternatives process","bullets":["Cash and equivalents $7.5M at Sept 30, 2025, down from $30.3M at Dec 31, 2024.","Net loss Q3 2025: $3.5M ($0.79/share) vs $10.6M ($5.32/share) in Q3 2024.","R&D expenses fell to $0.6M from $7.6M due to reprioritizing toward strategic alternatives.","Company continues strategic alternatives process to maximize stockholder value.","Expects start of TPST-1495 Phase 2 in collaboration with NCI and Cancer Prevention Clinical Trials Network."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-265937","json":"https://secwatch.observer/filing/0001193125-25-265937.json","markdown":"https://secwatch.observer/filing/0001193125-25-265937.md","text":"https://secwatch.observer/filing/0001193125-25-265937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312525265937/0001193125-25-265937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312525265937/tpst-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:16:43.731784+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}